PD-1抑制剂免疫相关不良反应的研究进展

免疫检查点抑制剂(immune checkpoint inhibitors,ICI)的应用是肿瘤治疗领域的重大突破,是恶性肿瘤患者新的选择和希望。国家食品与药品管理监督局(Chinese Food and Drug Administration,CFDA)批准程序性细胞死亡蛋白-1(programmed cell death protein 1,PD-1)免疫抑制剂用于多种肿瘤的治疗。但是PD-1抑制剂可引起自身免疫毒性,虽然大多数免疫相关不良反应(immune-related adverse events,irAEs)以1~2级为主,但仍有部分患者发生危及生命的3~4级免疫毒性反应。

Research progress of immune-related adverse reactions of PD-1 inhibitors

The application of immune checkpoint inhibitors(ICI)is a major breakthrough in the field of tumor treatment,and it is a new choice and hope for patients with malignant tumors.Chinese Food and Drug Administration(CFDA)has approved programmed cell death protein 1(PD-1)inhibitors for the treatment of a a variety of tumors.However,PD-1 inhibitors can cause autoimmune toxicity.Although most immune-related adverse events(irAEs)are in the level of grade 1–2,some patients still have life-threatening immunotoxic response in the level of grade 3–4.